Even the nihilists out there (anyone?) will be disheartened by this: A new nationwide survey finds that "top economists expect the already deep recession to get even worse this year."
That bad news, coming during a bear market that's decimated just about every stock investor's portfolio -- the rally of the past 30 days notwithstanding -- can only mean one thing.
It's time for penny stocks
Stocks were down more than 35% in 2008, and they've been about flat for 2009, so we can think of only one move to make right now: Buy penny stocks.
That's right, those tiny, low-priced lottery tickets have tremendous upside potential. They're our only shot to make up 2008's losses ... fast!
Who's with us?
After all, why would anyone want to buy $67 billion Abbott Laboratories
C'mon! The best we'll get out of Abbott is 8% to 10% annual growth, some share repurchases, and a dividend. But StemCells? Whoa! If it figures out stem cell therapeutics, we'll be filthy rich!
Alas, this is not investing. And if you thought we were serious about penny stocks, please check out an old anti-pennies rant of ours, "Why We Love Wild Penny Stocks."
See, investing in penny stocks is speculating, not investing. Vanguard founder Jack Bogle, in remarks here at Fool HQ in December, said that a single question will separate the wheat from the chaff: Are you an investor, or are you a speculator?
Speculating -- at all, but especially in penny stocks -- is not investing, now or ever. Indeed, Abbott will preserve your capital and earn you a healthy return. StemCells has the potential to go up, and the science is very interesting, but the company has almost no revenue and is burning cash. Unless you're an expert in analyzing its science, we'd advise you to stay away.
The story behind our headline
Advising folks to avoid penny stocks may seem obvious, but in fact, many "investors" are looking to buy up wild penny stocks precisely to make up for the losses they may have endured last year.
And this isn't particularly unusual. A forthcoming research paper by Alok Kumar of the University of Texas showed that "individual investors' demand for lottery-type stocks increases when economic conditions worsen."
Several years back, economists Richard Thaler and Eric Johnson speculated that there may exist a "break-even effect," where, given past losses, people are faster to turn to outcomes that offer a chance to break even. That would admittedly make sense in today's market.
After all, the market really has taken a nasty tumble. Shareholders of stalwarts such as Adobe Systems
Of course, the flight to "lottery-type stocks" would be a fabulous development ... if these stocks delivered lottery-type rewards. But if you've ever played the lottery, you know that you're way more likely to lose for the rest of your life than you are to win -- even just once.
And so it goes with penny stocks. Professor Kumar found that folks who buy penny stocks earn at least 4% lower average returns -- every year -- than those who don't.
Where to from here
In a column we wrote last year, we excerpted an insightful Richard Russell essay that compared an investor who had ample funds and an investor who was more desperate:
This fellow always feels pressured to "make money." And in return, he's always pressuring the market to "do something" for him. But sadly, the market isn't interested. When the little guy isn't buying stocks offering 1% or 2% yields, he's off to Las Vegas or Atlantic City trying to beat the house at roulette. ... And because the little guy is trying to force the market to do something, he's a guaranteed loser.
Not to put too fine a point on it, but buying wild penny stocks -- recession or expansion -- all but guarantees that you're an investing loser.
The Foolish bottom line
Penny stocks like StemCells offer more risk, lower returns, and the potential for total capital loss. We'd advise you, then, to stray from speculating and stick with investing.
But if it is room to run and wide market opportunities you're after, we'd advise you to look at international stocks. As co-advisor of our Motley Fool Global Gains service (Tim) and a contributing author to the international-investing chapter of our most recent book (Brian), we believe the growth potential of many foreign stocks -- even some of the stalwarts -- could lead to multibagger returns at today's prices.
Right now, we're offering a full-privileges tour of Global Gains free for 30 days. Come tour the service and get our team's top five foreign stocks for right now, by just clicking here.
This article was first published Feb. 5, 2009. It has been updated.
Already subscribe to Global Gains? Log in at the top of this page.
Tim Hanson is co-advisor of Global Gains and does not own shares of any company mentioned. Brian Richards is assistant to the regional manager, Dunder Mifflin Scranton, and does not own any companies mentioned. NVIDIA is a Stock Advisor recommendation. The Motley Fool is investors writing for investors.